CO5150215A1 - Composiciones que tienen estabilidad mejorada - Google Patents

Composiciones que tienen estabilidad mejorada

Info

Publication number
CO5150215A1
CO5150215A1 CO00001048A CO00001048A CO5150215A1 CO 5150215 A1 CO5150215 A1 CO 5150215A1 CO 00001048 A CO00001048 A CO 00001048A CO 00001048 A CO00001048 A CO 00001048A CO 5150215 A1 CO5150215 A1 CO 5150215A1
Authority
CO
Colombia
Prior art keywords
reducing agent
aforementioned
asset
improved stability
composition
Prior art date
Application number
CO00001048A
Other languages
English (en)
Inventor
Douglas Joseph Dobrozsi
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5150215A1 publication Critical patent/CO5150215A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se relaciona con una composición líquida que tiene la estabilidad mejorada que comprende un activo farmacéutico, un disolvente para solubilizar el activo antes mencionado, y un agente reductor para mejorar la estabilidad del activo antes mencionado en la composición antes mencionada, en donde el agente reductor mencionado se selecciona del grupo que consiste de las sales de metabisulfito y bisulfito, incluyendo sus sales de sodio y potasio; ditiotreitol; tiourea; tiosulfato sódico; ácido tioglicólico; terc-butil-hidroquinona (TBHQ); acetil-cisteina; hidroquinona y mezclas de éstos y donde dicho agente reductor comprende de 0,005% a 1,000%, de la composición y método para su aplicación .
CO00001048A 1999-01-11 2000-01-11 Composiciones que tienen estabilidad mejorada CO5150215A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11537899P 1999-01-11 1999-01-11
US15654099P 1999-09-29 1999-09-29

Publications (1)

Publication Number Publication Date
CO5150215A1 true CO5150215A1 (es) 2002-04-29

Family

ID=26813133

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00001048A CO5150215A1 (es) 1999-01-11 2000-01-11 Composiciones que tienen estabilidad mejorada

Country Status (15)

Country Link
US (1) US20020082307A1 (es)
EP (1) EP1146876A2 (es)
JP (1) JP2002534464A (es)
KR (1) KR20010101476A (es)
CN (1) CN1336822A (es)
AU (1) AU771478B2 (es)
BR (1) BR0007473A (es)
CA (1) CA2356944A1 (es)
CO (1) CO5150215A1 (es)
CZ (1) CZ20012492A3 (es)
HU (1) HUP0105028A3 (es)
NO (1) NO20013441D0 (es)
PE (1) PE20001424A1 (es)
TR (1) TR200101928T2 (es)
WO (1) WO2000041694A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7757855B2 (en) 2002-02-08 2010-07-20 The Procter & Gamble Company Sachet constructions
DK2522365T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
ES2598114T3 (es) * 2007-08-31 2017-01-25 Archimedes Development Limited Composiciones farmacéuticas no acuosas
US7914828B2 (en) * 2008-10-17 2011-03-29 Levine Brian M Combination herbal product to benefit respiratory tract
US8361519B2 (en) 2010-11-18 2013-01-29 Aadvantics Pharmaceuticals, Inc. Combination herbal product to benefit respiratory tract in people exposed to smoke
CN104027326B (zh) * 2013-03-04 2017-09-01 天津康鸿医药科技发展有限公司 盐酸氨溴索雾化吸入剂及其制备方法和应用
WO2018183203A1 (en) * 2017-03-27 2018-10-04 DXM Pharmaceutical, Inc. Packaged multi-dose liquid drug formulation
US11234897B2 (en) 2017-03-27 2022-02-01 DXM Pharmaceutical, Inc. Packaged multi-dose liquid dextromethorphan hydrobromide formulation
JP2021529760A (ja) * 2018-06-29 2021-11-04 ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドＪｏｈｎｓｏｎ ＆ Ｊｏｈｎｓｏｎ Ｃｏｎｓｕｍｅｒ Ｉｎｃ． 活性物質の送達のための三次元マイクロ流体デバイス

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100898A (en) * 1990-01-25 1992-03-31 Richardson-Vicks Inc. Antitussive liquid compositions containing dyclonine
WO1995019759A1 (en) * 1994-01-24 1995-07-27 The Procter & Gamble Company Process for solubilizing difficultly soluble pharmaceutical actives
US5510389A (en) * 1994-03-02 1996-04-23 The Procter & Gamble Company Concentrated acetaminophen solution compositions
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
AU7916798A (en) * 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat

Also Published As

Publication number Publication date
HUP0105028A3 (en) 2003-05-28
WO2000041694A2 (en) 2000-07-20
NO20013441L (no) 2001-07-11
BR0007473A (pt) 2001-10-16
PE20001424A1 (es) 2001-01-05
WO2000041694A3 (en) 2000-11-30
JP2002534464A (ja) 2002-10-15
CA2356944A1 (en) 2000-07-20
AU771478B2 (en) 2004-03-25
CZ20012492A3 (cs) 2001-11-14
TR200101928T2 (tr) 2001-11-21
NO20013441D0 (no) 2001-07-11
US20020082307A1 (en) 2002-06-27
EP1146876A2 (en) 2001-10-24
CN1336822A (zh) 2002-02-20
AU2847500A (en) 2000-08-01
HUP0105028A2 (hu) 2002-05-29
KR20010101476A (ko) 2001-11-14

Similar Documents

Publication Publication Date Title
CO5150215A1 (es) Composiciones que tienen estabilidad mejorada
UY27320A1 (es) Nuevas composiciones farmacéuticas
YU39800A (sh) Derivati sulfonamida kao pro-lekovi inhibitora aspartil proteaze
DE60137399D1 (de) Propansäurederivate die die Bindung von Integrinen an ihre Rezeptoren hemmen
CO5721018A2 (es) Pelicula detergente de dosis de unidad
PE20010627A1 (es) Composiciones que tienen estabilidad mejorada
NO20083027L (no) Kontrollert frigivelses-fastformpreparat
BR9714310A (pt) Composição farmacêutica
JP2007521234A (ja) 尋常性ざ瘡の治療薬及び使用方法
CO5011119A1 (es) Jarabe antihistaminico estabilizado
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
ES2184310T3 (es) Formulacion autoemulsionante para compuestos lipofilos acidos.
CL2009001680A1 (es) Composiciones agroquimicas que comprenden a)metconazol o una sal del mismo y b)un acido carboxilico alifatico de cadena lineal o ramificada, saturado o no saturado y donde la relacion molar de (b) respecto de (a) es superior a 1
CY1111905T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα εναν επιλεκτικο αναστολεα της αμινοπεπτιδασης α, ειδικα τον ec33, για τη μειωση της αρτηριακης πιεσεως
ATE526390T1 (de) Hochkonzentrierte tensidzusammensetzungen und verfahren
ATE554792T1 (de) Stabiles wachstumshormon-flüssigformulierung
BR0213019A (pt) Formulações melhoradas para neutralização de substâncias tóxicas quìmicas, biológicas e industrias
AR032362A1 (es) Formulacion topica estable de una emulsion de aceite en agua y proceso para su preparacion
BR0206353A (pt) Aperfeiçoamentos em, ou relacionados a composições detergentes lìquidas
AR068327A1 (es) Composicion farmaceutica liquida estable a base de trazodona
CA2442875A1 (fr) Nouveau procede de synthese industriel du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylique, et application a la synthese des sels bivalents del'acide ranelique et de leurs hydrates
BR0009214A (pt) Composições aquosas estáveis contendo umcomposto de silìcio
AR046143A1 (es) Composicion farmaceutica que contiene un derivado de tiourea con solubilidad y biodisponiblidad mejoradas